^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ER positive + PGR negative + HER-2 negative

    i
    Other names: ESR1, Era, ESR, NR3A1, ER, ER beta, ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
    Entrez ID:
    2064; 2099; 5241
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    2years
    Secretory Carcinoma of the Breast Mimicking Invasive Ductal Carcinoma: A Case Report. (PubMed, Am J Case Rep)
    The mainstay of treatment is partial or total mastectomy. Data on the benefits of adjuvant endocrine therapy, chemotherapy, and radiotherapy are inconclusive.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
    |
    ER positive • HER-2 negative • NTRK3 fusion • ETV6-NTRK3 fusion • ER positive + PGR negative + HER-2 negative • PGR negative
    |
    Oncotype DX Breast Recurrence Score®Test
    3years
    A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape. (PubMed, J Transl Med)
    Overall, this study revealed five heterogeneous immune subtypes among ER+/PR-/HER2- breast cancer, also provided important implications for clinical translations.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    |
    ER positive • HER-2 negative • ER positive + PGR negative + HER-2 negative • PGR negative
    4years
    Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER HER2 Breast Cancer: A Prospective Phase II Study. (PubMed, Clin Breast Cancer)
    Our prospective study showed that a TC regimen as NAC achieved a high clinical response rate in stage II to III ER/HER2 breast cancer. A TC regimen without anthracycline as NAC might be one of the options for patients with ER/HER2 breast cancer without high-risk factors including progesterone receptor negativity.
    Clinical • P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative • ER positive + PGR negative + HER-2 negative
    |
    docetaxel • cyclophosphamide intravenous